Members are listed alphabetically.
Click on thumbnail to view profile.
Return to ICT Main Page
We are Abraxis Oncology, tapping into our creativity to
outsmart tumor biology, attack cancer cells, and surpass
expectations. Our imaginations have free reign to attempt
new ideas, lead us down unexplored pathways, and
respectfully challenge established paradigms. With this
creative freedom comes innovation-the essential spark in the
quest for new answers and novel treatments. At Abraxis
Oncology, we are devoted entirely to developing and
promoting innovative, next-generation cancer therapies.
Abraxis Oncology is the proprietary division of
Abraxis BioScience.
Abraxis BioScience is an integrated global biopharmaceutical
company focused on the discovery, development and delivery
of next-generation therapeutic moieties for the treatment of
life-threatening diseases.
http://www.abraxisbio.com
Advaxis is a discovery stage biotech
company developing bioengineered Listeria
monocytogenes for use as a live cancer vaccine vector.
Listeria is safe to use as a live
vaccine vector. As an environmental pathogen found in our food
supply and routinely ingested, it is a pathogen with which we
have an immune relationship. It is not laterally transmissible,
and other than the immunosurpressed and 3rd trimester
pregnant or nursing women Listeria is safe in most
people,. In the event of a problem Listeria infection
can be sterilized rapidly with a low dose of a variety of common
antibiotics.
Listeria is a pathogen that infects
the immune system and offers an unusual ability to manipulate a
number of important immune mechanisms in a simultaneous and
integrated fashion, including: stimulation of effector cells
(CD4+, CD8+, DC, macrophages, etc),
stimulation of many immune mediators (Th-1 cytokines, chemokines,
co-stimulatory molecules, GM-CSF and others), maturation of
immature immune cells and the stimulation of monopoesis, as well
as the ability to remove inhibitory influences on the immune
response (Tregs, immature myeloid cells). By infecting Antigen
Presenting Cells (APC) Listeria vaccines have the ability
to redirect a whole body immune response and focus it on which
ever tumor specific antigen is bioengineered into the
construct. By using a proprietary fusion protein in which the
microbe is engineered to secrete a tumor specific antigen fused
to a Listeria protein dramatic increases in efficacy have
been observed.
The first live Listeria vaccine in
the clinic is Lovaxin C (Lm-LLO-E7) directed against the HPV-16
E7 antigen presumed to cause most of the cervical cancer seen in
the US. In Phase I only a flu-like syndrome was associated with
Lovaxin C administration. Various studies to test Lovaxin C in
early stage disease, adjuvant models, and other protocols are
planned.
Advaxis is pleased to be associated with
GOG in the development of this agent.
http://www.advaxis.com
Amgen is a global biotechnology company that discovers, develops, manufactures
and markets important human therapeutics based on advances in cellular and
molecular biology.
http://www.amgen.com
The
new corporate mission statement, featuring the slogan
“Bayer: Science For A Better Life,” summarizes the Group’s
goals, strategies and values. In the future, Bayer will focus on
innovation and growth in the areas of health care, nutrition and
high-tech materials.
The mission statement underscores
Bayer’s willingness as an inventor company to help shape the
future and our determination to come up with innovations that
benefit humankind. Of special importance in this respect are new
products emerging from Bayer’s active substance research, the
consumer health business, the growth markets of Asia and new
areas such as biotechnology and nanotechnology.
http://www.bayer.com
BD
Diagnostics - TriPath
In December 2006, BD (Becton,
Dickinson and Company) acquired TriPath Imaging, Inc., a maker
of innovative solutions to
improve the clinical management of cancer. This strategic acquisition aligns
innovative new technologies
with BD’s existing business strategies and is a natural complement to
ongoing internal research
programs in its BD Diagnostics and BD Biosciences segments.
These oncology management
tools are intended to span cancer screening, diagnosis, prognosis and
therapy monitoring, especially
for cancers affecting women’s health, including breast, cervical and
ovarian. This acquisition also
demonstrates BD’s commitment to bringing new technologies and
innovation to difficult
problems in healthcare, which is in line with the Company’s purpose of “Helping
all people live healthy
lives.”
About BD
BD, a leading global medical
technology company that manufactures and sells medical devices,
instrument systems and
reagents, is dedicated to improving people’s health throughout the world.
BD is focused on improving
drug therapy, enhancing the quality and speed of diagnosing infectious
diseases, and advancing
research and discovery of new drugs and vaccines. The Company’s capabilities
are instrumental in combating
many of the world’s most pressing diseases. Founded in 1897 and
headquartered in Franklin
Lakes, New Jersey, BD employs approximately 27,000 people in approximately
50 countries throughout the
world. The Company serves healthcare institutions, life science researchers,
clinical laboratories,
industry and the general public. For more information, please visit
http://www.bd.com
Bristol-Myers Squibb is the world leader in providing life-saving
and life-extending therapies for people with cancer. All of the
company's considerable resources and expertise in oncology are
marshaled toward the single goal of providing safer and more
effective anticancer medicines. The mission of Bristol-Myers
Squibb Oncology is to extend and enhance the lives of people
living with cancer.
http://www.BMS.com
Caris MPI provides
advanced molecular analyses of patient samples through
diagnostic and prognostic testing services using proprietary
genomic and proteomic profiling to provide critical
information to physicians treating cancer and other complex
diseases. The company has strategic relationships with the
International Genomics Research Institute and the Biodesign
Institute of Arizona State University.
www.molecularprofiling.com
Celgene Corporation is a global, integrated, biopharmaceutical
company primarily engaged in the discovery, development and
commercialization of innovative therapies designed to treat
cancer and immune-inflammatory related diseases.
www.celgene.com
CTI is committed to developing, acquiring, and commercializing innovative
treatments for cancer. In its pursuit of making cancer more treatable, the
Company is developing a diversified portfolio of oncology drugs. Our research
and in-licensing activities are concentrated on identifying new, less toxic,
and more effective ways to treat cancer.
CTI's product pipeline includes one marketed drug, TRISENOX, and several investigational
drugs that may address the therapeutic limitations of conventional cancer therapies.
Our most advanced investigational drug, XYOTAX (polyglutamate paclitaxel), is currently
in Phase III for non-small-cell lung and ovarian cancers. Together, these drug candidates
represent our progress in making cancer a more treatable disease.
http://www.cticseattle.com
Exiqon
Diagnostics, a division of Exiqon A/S, is a leader in
personalizing medicine for cancer patients. Exiqon Diagnostics
is dedicated to developing and performing novel molecular and
cell-based oncology assays to help physicians individualize and
optimize treatment selection for their patients.
The Company
offers a broad range of clinical laboratory services including
the Oncotech EDR™ Assay and molecular biomarker testing. By
utilizing proprietary LNA™ technology and miRNA biomarkers,
Exiqon Diagnostics is establishing the next generation of
molecular diagnostics for oncology. Exiqon Diagnostics has
performed oncology services for more than 150,000 cancer
patients from over 1000 hospitals throughout North America and
Europe. Exiqon Diagnostics is the trade name for Oncotech,
Inc., a wholly owned subsidiary of Exiqon A/S.
www.exiqon.com
Genentech is a leading biotechnology company that
discovers, develops, manufactures and commercializes biotherapeutics for
significant
unmet medical needs. Genentech manufactures and commercializes several major
oncology drugs include Herceptin, Rituxan, Avastin and Tarceva.
http://www.genentech.com
Genzyme
Biosurgery is the leader for adhesion prevention following
abdominopelvic surgery. Seprafilm®Adhesion Barrier
is a bioresorbable, site-specific barrier that separates
adhesiogenic tissue surfaces during the critical 7-day period of
peritoneal healing. In a pivotal abdominal clinical study,
Seprafilm® Adhesion Barrier patients were 8.5 times
more likely to be free of adhesions compared to control patients
(Becker 1996). No statistically significant differences were
observed in the incidence of adverse events comparing Seprafilm®
and control patients. Sepramesh®IP Bioresorbable
Coating/Permanent Mesh is indicated for the reconstruction of
soft tissue deficiencies, such as for the repair of hernias. It
is a polypropylene mesh co-knitted with polyglycolide (PGA)
fibers, which is coated on one side with a bioresorbable HA/CMC
hydrogel that minimizes unwanted adhesions between the mesh and
underlying viscera.
http://www.genzyme.com
GlaxoSmithKline
is a world leading research based pharmaceutical company with a
powerful combination of skills and resources that provides a
platform for delivery of strong growth in today’s rapidly
changing environment. GlaxoSmithKline’s mission is to improve
the quality of human life by enabling people to do more, feel
better and live longer.
GlaxoSmithKline
also has leadership in four major therapeutic areas – anti-infectives,
central nervous system, respiratory and
gastro-intestinal/metabolic. In addition, GlaxoSmithKline is a
leader in the important area of vaccines and has a growing
portfolio of oncology products, including Hycamtin (topotecan
HCL) for relapsed ovarian cancer and Navelbine (vinorelbine
tartrate). GlaxoSmithKline Oncology also has a dedicated sales
force committed to women’s cancers, including oncology medical
scientists and oncology nurse educators.
http://www.glaxosmithkline.com
ImClone Systems Incorporated is a fully integrated
global biopharmaceutical company committed to advancing
oncology care by developing and commercializing a
portfolio of targeted biologic treatments designed to
address the medical needs of patients with a variety of
cancers.
Eli Lilly and Company is a leading innovation-driven
corporation and is developing a growing portfolio of best-in-class
pharmaceutical products by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Indiana, Lilly provides
answers – through medicines and information – for some of the world’s most
urgent medical needs.
Lilly Oncology is committed to providing comprehensive healthcare
solutions – answers that matter – for oncologists and cancer patients around
the world through the discovery and development of breakthrough cancer medicines.
http://www.lilly.com
The mission of Merck is to provide society with
superior products and services by developing innovations and
solutions that improve the quality of life and satisfy customer
needs, and to provide employees with meaningful work and
advancement opportunities, and investors with a superior rate of
return.
Merck & Co., Inc.
is a global research-driven pharmaceutical company dedicated to
putting patients first. Established in 1891, Merck discovers,
develops, manufactures and markets vaccines and medicines to
address unmet medical needs. The company also devotes extensive
efforts to increase access to medicines through far-reaching
programs that not only donate Merck medicines but help deliver
them to the people who need them. Merck also publishes unbiased
health information as a not-for-profit service. For more
information, visit
www.merck.com.
www.merck.com
Morphotek®, Inc., a
subsidiary of Eisai Corporation of North America, is a
biopharmaceutical company specializing in the development of
protein and antibody products through the use of a novel and
proprietary gene evolution technology. The technology has been
successfully applied to a broad variety of cell lined and
organisms to yield genetically diverse offspring that are
suitable for pharmaceutical product development in the areas of
antibody therapeutics, protein therapeutics, product
manufacturing, drug target discovery, and improved output traits
for commercial applications. The company is currently focusing
its platform on the development and manufacturing of therapeutic
antibodies for the treatment of cancer, inflammation and
infections disease. For more information, please visit
http://www.morphotek.com
Our
mission is to become the world's premier oncology company by
consistently discovering, developing, and producing broadly
available novel therapies that improve and extend the lives of
cancer patients.
http://www.novartisoncology.com
Onyx Pharmaceuticals, Inc. is a biopharmaceutical
company committed to improving the lives of people with cancer
by ;changing the way cancer is treatedTM. The
company, in collaboration with Bayer HealthCare Pharmaceuticals,
Inc., is developing and marketing Nexavar®, a
small molecule drug. Nexavar is currently approved for
the treatment of liver cancer and advanced kidney cancer.
Additionally, Nexavar is being investigated in several ongoing
trials in non-small cell lung cancer, melanoma, breast cancer,
and other cancers. For more information about Onyx, visit the
company's website at:
www.onyx‑pharm.com
At Ortho Biotech Products, l.P., we’re in the business of
helping seriously ill people get better and feel stronger. We
have products that may help extend and enhance people’s lives.
We market prescription medications for correcting the anemias
associated with cancer chemotherapy for patients with nonmyeloid
malignancies; AZT-treated, HIV-infected patients; chronic kidney
disease patients not on dialysis; and elective, noncardiac,
nonvascular, surgery patients. We also provide treatments for
organ transplant rejection, a rare form of leukemia, cancer pain
and life-threatening fungal infections.
We are a global organization with headquarters in Raritan, New
Jersey, and Saunderton, United Kingdom, and are a member of the
Johnson & Johnson family of companies. We have a passion for the
work we do and compassion for the patients and providers we
serve.
We continually seek new ways of meeting the needs of the health
care community through new products and technologies, and new
programs that help doctors, nurses, patients, caregivers,
patient advocates and other health care professionals derive
greater benefit from what we have to offer.
We're proud of what we've accomplished and how many lives we've
made better. We also take great pride in the fact that those
we've helped feel the same way.
http://www.orthobiotech.com
OSI Pharmaceuticals is committed
to "shaping medicine and changing lives" by discovering, developing and
commercializing high-quality and novel pharmaceutical products designed to
extend life or improve the quality of life for patients with cancer, eye
diseases and diabetes. OSI’s oncology team, (OSI) Oncology, is focused on
developing molecular targeted therapies designed to change the paradigm of
cancer care. OSI's flagship product, Tarceva® (erlotinib), is the
first drug discovered and developed by OSI to obtain FDA approval and the only
EGFR inhibitor to have demonstrated the ability to improve survival in both
non-small cell lung cancer and pancreatic cancer patients in certain settings.
For more information on OSI, please visit
http://www.osip.com
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the development and commercialization of innovative
oncology products to impact the lives of people with cancer.
We are currently focusing our development efforts on
picoplatin, a new generation platinum chemotherapy agent with
the potential to become a platform product addressing multiple
indications, combinations and formulations. Picoplatin has an
improved safety profile compared to existing platinum-based
chemotherapeutics. It was designed to overcome platinum
resistance associated with chemotherapy in solid tumors and
delay time to relapse. We are studying picoplatin in multiple
cancer indications, combinations and formulations.
Our business strategy is to form partnerships to support and
expand our clinical programs and commercial opportunities and to
build a diverse portfolio of oncology product candidates. As
part of this strategy, we are collaborating with The Scripps
Research Institute on the discovery of novel, small-molecule,
multi-targeted protein kinase inhibitors as therapeutic agents
to treat cancer.
Poniard is headquartered in South San Francisco. We are
traded on the NASDAQ Global Market under the symbol PARD.
www.poniard.com.
Precision Therapeutics iis
a diagnostics services company dedicated to providing physicians
and patients with actionable clinical information to personalize
cancer treatments. Precision’s ChemoFx®, a proprietary live
tumor cell-based platform, measures an individual patient’s
tumor sensitivity and resistance to a range of therapeutic
alternatives under consideration by a physician.
http://www.ptilabs.com
Pfizer is a research-based global pharmaceutical company dedicated to helping people live longer,
healthier lives. It invests more than $2 billion annually in research, searching for treatments and cures
for cancer, osteoporosis, diabetes, Alzheimer's disease, arthritis, heart disease, sexual dysfunction, and a
wide variety of other diseases. Pfizer is also a leader in animal health, offering medicines for companion and
farm animals, and in consumer health care products.
http://www.pfizer.com
Regeneron Pharmaceuticals, Inc.
is a fully integrated
biopharmaceutical company that discovers, develops, and
commercializes medicines for the treatment of serious medical
conditions. Regeneron has therapeutic candidates for the
potential treatment of cancer, eye diseases, and inflammatory
diseases and has preclinical programs in other diseases and
disorders.
New Drug
Development Technology Platforms
Regeneron has developed the VelociSuite of technologies,
comprising VelociGene®, VelociMouse™,
VelocImmune®, and VelociMab™, which increases the
efficiency and decreases the time involved in progressing from
early discovery efforts through drug candidate generation.
Together, these technologies allow Regeneron scientists to
determine the best targets for therapeutic intervention, and
then rapidly generate high-quality, fully human antibodies as
drug candidates addressing these targets.
www.regeneron.com
The
sanofi-aventis Group is the world’s 3rd largest pharmaceutical
company, ranking number 1 in Europe. Backed by a world-class
R&D organization, sanofi-aventis is developing leading positions
in seven major therapeutic areas: cardiovascular disease,
thrombosis, oncology, diabetes, central
nervous system,
internal medicine, vaccines. The sanofi-aventis Group is listed
in Paris (EURONEXT : SAN) and in New York (NYSE : SNY). Please
visit sanofi-aventis at
www.sanofi-aventis.com.
